Asciminib Roll-over Study

This is a long term safety study for patients who have completed a Novartis sponsored asciminib study and are judged by the investigator to benefit from continued treatment

Trial Details

NCT ID
NCT04877522
Phase
PHASE4
Sponsor
Novartis Pharmaceuticals
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • Asciminib single agent
  • Imatinib
  • Nilotinib
  • Bosutinib
  • Dasatinib
  • Asciminib single agent pediatric formulation
Locations (sample)
  • Ann Arbor, Michigan, United States|42.27756,-83.74088
  • New York, New York, United States|40.71427,-74.00597
  • Portland, Oregon, United States|45.52345,-122.67621
  • Dallas, Texas, United States|32.78306,-96.80667
  • Houston, Texas, United States|29.76328,-95.36327

Key Eligibility Criteria

  • Participant with PH+ CML or PH+ ALL currently receiving treatment with asciminib (single agent or in combination with imatinib, nilotinib or dasati…
  • Participant has demonstrated compliance on the parent study protocol and is willing and able to comply with scheduled visits, treatment plans and a…
  • Key Exclusion Criteria:
  • Participant has been discontinued from parent study treatment.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →